Postpolymerization Modification of Poly(2-vinyl-4,4-dimethyl azlactone) as a Versatile Strategy for Drug Conjugation...

Area of Science:

• Polymer Chemistry
• Biomedical Engineering
• Drug Delivery Systems

Background:

• Controlled radical polymerization has limitations including batch inconsistencies and limited monomer accessibility.
• Postpolymerization modification offers a route to overcome these challenges in polymer synthesis.
• Poly(2-vinyl-4,4-dimethyl azlactone) (PVDMA) is explored as a versatile polymer scaffold.

Purpose of the Study:

• To investigate the postpolymerization modification of PVDMA scaffolds with small molecule drugs.
• To evaluate the biocompatibility and drug release characteristics of modified PVDMA.
• To assess the in vivo pharmacokinetics, biodistribution, and antitumor efficacy of PVDMA-based polymer-drug conjugates.

Main Methods:

• Physicochemical characterization techniques were employed to confirm polymer modification.
• In vitro studies assessed cellular biocompatibility and intracellular drug liberation.
• In vivo studies evaluated pharmacokinetics, biodistribution, and antitumor efficacy in a 4T1 triple-negative breast cancer model.

Main Results:

• PVDMA scaffolds were successfully modified with coumarin, doxorubicin, and camptothecin.
• Coumarin-modified PVDMA exhibited high cellular biocompatibility with intracellular drug release.
• PVDMA-drug conjugates showed route-dependent accumulation, efficient tumor uptake, and significant tumor growth inhibition.

Conclusions:

• PVDMA serves as a versatile platform for creating tunable, stimuli-responsive polymer-drug conjugates.
• This approach overcomes limitations of traditional controlled radical polymerization.
• PVDMA-based conjugates hold promise for targeted cancer therapy, particularly for triple-negative breast cancer.